Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Harmony Biosciences Holdings, Inc. Common Stock

HRMY

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Last trade $32.83
Day change -$0.135 (-0.41%)
Day range $32.44 – $33.32
Volume 260,142
Market cap $1.94B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.94B
Price / earnings
10.84×
Price / book
1.81×
Price / sales
1.96×
EV / sales
1.45×
EV / EBITDA
5.87×

Profitability

Earnings per share
$3.04
Return on assets
12.08%
Return on equity
16.66%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.14×
Current ratio
3.44×
Quick ratio
3.42×
Cash ratio
2.38×

Cash flow

Price / cash flow
5.99×
Price / free cash flow
5.99×
Free cash flow
$322.93M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for HRMY, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$268.92M$261.28M$215.39M$243.78M$239.46M$200.49M$184.73M$201.27M
Cost of revenue$80.69M$63.2M$44.51M$68.55M$59.65M$38.15M$31.99M$54.41M
Gross profit$188.23M$198.08M$170.88M$175.23M$179.81M$162.34M$152.74M$146.86M
Selling, general and administrative$62.37M$62.17M$64.2M$86.74M$59.36M$64M$61.95M$56.47M
Research and development$71.66M$46.6M$69.38M$49.93M$54.96M$50.16M$34.54M$34.67M
Total operating expenses$134.03M$108.77M$133.58M$136.67M$114.32M$114.16M$96.49M$91.13M
Operating income$54.2M$89.32M$37.29M$38.56M$65.49M$48.18M$56.25M$55.73M
Interest expense-$3.06M-$2.92M-$3.23M-$3.55M-$3.62M-$3.48M-$3.84M-$4.21M
Income before taxes$59.25M$93.27M$39.69M$40.76M$67.49M$49.64M$57.18M$56.16M
Income taxes$11.05M$17.83M$7.2M$18.27M$16.63M$9.86M$11.62M$6.68M
Net income$48.2M$75.43M$32.49M$22.49M$50.87M$39.78M$45.56M$49.48M
Net income attributable to common shareholders$48.2M$75.43M$32.49M$22.49M$50.87M$39.78M$45.56M$49.48M
EBITDA$72.09M$83.36M$43.26M$45.99M$83.38M$42.23M$62.21M$61.7M
Basic earnings per share$0.83$1.30$0.56$0.39$0.88$0.69$0.79$0.87
Diluted earnings per share$0.81$1.28$0.55$0.38$0.87$0.68$0.78$0.85

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

AASM releases roadmap to improve women’s sleep health

The American Academy of Sleep Medicine released a comprehensive report and multiyear roadmap to improve women's sleep health, identifying priority areas including fertility, pregnancy, postpartum health, menopausal transitions, and sleep disorders. The report highlights gaps in research, clinical care, and policy, calling for increased clinical trial representation, research funding, and tailored interventions for women.

Zacks Investment Research

HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth

Harmony Biosciences reported Q3 EPS of 81 cents, missing consensus estimates of $1.00, despite 12% revenue growth to $269 million. Higher R&D spending, a $25 million MSN milestone charge, and royalty expenses pressured profitability. The company reaffirmed its 2026 Wakix revenue guidance of $1-$1.04 billion, supported by sustained patient demand and 400 net patient additions. The pipeline includes promising Phase I results for BP-205 and ongoing late-stage studies for pitolisant formulations and epilepsy programs.

Zacks Investment Research

Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth

Harmony Biosciences is expected to report Q3 2026 earnings on November 4, with Wall Street anticipating 14.9% YoY EPS growth to $1.00 per share and 13.1% revenue growth to $270.87 million. However, a negative Earnings ESP of -12.00% combined with recent downward estimate revisions suggests the stock may not beat consensus expectations, despite carrying a Zacks Rank #1 rating.

Zacks Investment Research

BHC Q3 Earnings Preview: Here's What You Should Know

Bausch Health Companies (BHC) is scheduled to report Q3 2026 results on October 28 with consensus estimates of $2.75 billion in sales and $1.08 EPS. The company has a Zacks Rank of 2 (Buy) with 0% Earnings ESP, suggesting limited upside surprise potential. Growth is expected across Salix (driven by Xifaxan pricing and volume), Bausch + Lomb Vision Care and Surgical divisions, and international operations, though the stock has already gained 15.4% over the past six months.

Zacks Investment Research

TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data

Tango Therapeutics shares dropped 16.4% after updated phase I/II data showed an 82% objective response rate in pancreatic cancer, down from 92% in June's initial readout. While the combination demonstrated durable disease control with 88% nine-month progression-free survival, the company also announced a 14% workforce reduction and R&D reprioritization focusing on PRMT5 programs. Tango plans to initiate a phase III study in 2027.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.